Jeffrey Glassberg, MD
Emergency Medicine · New York, NYNPI 1225291511
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,382 of the $4,505 with a category attached, or 97.3%. CSL Behring accounts for 68.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $3,065 and has fallen 96.0% since, to $123 in 2024. Among emergency medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3 payments — averaging $1501.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$3K
- Novartis$1K
- Agios Pharmaceuticals, Inc.$123
Across 31 payments — averaging $17,962 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$470K
- Pfizer$45K
- Global Blood Therapeutics, Inc.$42K
What the payments were for
- Consulting fees$4,38297%
- Food & beverage$1233%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 1 | $3,065 |
| Novartis | 1 | $1,317 |
| Agios Pharmaceuticals, Inc. | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,505 in reported general payments places this provider in the 95th percentile of 4,167 emergency medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxbrytaVoxelotor | 38 | $476,571 |
| XareltoRivaroxaban | 12 | $9,183 |
| EliquisApixaban | 12 | $6,675 |
| Hydroxyurea | 90 | $1,652 |
| Oxycodone Hcl | 13 | $212 |
| Gabapentin | 19 | $151 |
| Folic Acid | 18 | $50 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in New York
- Joseph HabbousheNew York$309K
- Sohan ParekhNew York$174K
- Benjamin AbellaNew York$143K
- Leroy NicklesNew York$64K
- Bret NelsonNew York$58K
- Yves DuroseauNew York$44K
- Patrick MaherNew York$20K
- Andy JagodaNew York$18K
- Jonathan St GeorgeNew York$13K
- Steven KaplanNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.